Case Study: Leading Pharmaceutical Company achieves rapid imaging scale-up and accelerated enrollment for Phase 3 Alzheimer’s trial with Perceptive

Rapid Scale-up of Imaging Services for Phase 3 Alzheimer’s Clinical Trial

Leading Pharmaceutical Company engaged Perceptive to provide imaging core lab services for a phase 3 trial of a breakthrough amyloid‑targeting therapy for early symptomatic Alzheimer’s disease. The sponsor required Perceptive to stand up a full imaging solution in a matter of months to support accelerated enrollment across hundreds of sites, ensure rapid PET eligibility reads and quantitative analyses, and manage the operational and regulatory demands of a large, global 30‑month study.

Perceptive deployed its imaging platform, global reviewer network and established operational processes to train sites, onboard over 390 sites in under three months, and conduct high‑volume reads and analytics. The team reviewed ~6,900 eligibility scans in seven months (peak >100/day), processed ~9,000 Amyloid PET and ~4,500 Tau PET scans with query response times ≈1 day and eligibility read TATs of ~2–4 days, supporting 1,736 enrolled subjects; the imaging data helped demonstrate amyloid reduction and slowed clinical decline and contributed to the compound’s FDA approval in 2024.